scispace - formally typeset
M

Myrlene A. Staten

Researcher at National Institutes of Health

Publications -  39
Citations -  3536

Myrlene A. Staten is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Type 2 diabetes & Prediabetes. The author has an hindex of 18, co-authored 35 publications receiving 2988 citations. Previous affiliations of Myrlene A. Staten include Stanford University & Amgen.

Papers
More filters
Journal ArticleDOI

Perioperative safety in the longitudinal assessment of bariatric surgery.

TL;DR: The overall risk of death and other adverse outcomes after bariatric surgery was low and varied considerably according to patient characteristics, andExtreme values of body-mass index were significantly associated with an increased risk of the composite end point, whereas age, sex, race, ethnic group, and other coexisting conditions were not.
Journal ArticleDOI

Vitamin D Supplementation and Prevention of Type 2 Diabetes

TL;DR: Among persons at high risk for type 2 diabetes not selected for vitamin D insufficiency, vitamin D3 supplementation at a dose of 4000 IU per day did not result in a significantly lower risk of diabetes than placebo.
Journal ArticleDOI

Long-term Outcomes of Bariatric Surgery: A National Institutes of Health Symposium

TL;DR: High-quality evidence shows that bariatric surgical procedures result in greater weight loss than nonsurgical treatments and are more effective at inducing initial type 2 diabetes mellitus remission in obese patients.
Journal ArticleDOI

Serum leptin concentration, obesity, and insulin resistance in Western Samoans: cross sectional study.

TL;DR: The strong relation of leptin with obesity is consistent with leptin production being proportional to mass of adipose tissue, but the independent association with insulin concentration suggests a possible role in insulin resistance or hyperinsulinaemia.
Journal ArticleDOI

Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

TL;DR: This pragmatic, unmasked clinical trial aims to compare commonly used diabetes medications, when combined with metformin, on glycemia-lowering effectiveness and patient-centered outcomes and provide guidance to clinicians about the most appropriate medications to treat T2DM.